Regional analysis of a cohort compassionate-use program and early access program with cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mcrpc) previously treated with docetaxel
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2015Título de revista
Asia-Pacific Journal of Clinical Oncology
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)